What determines success as companies move from “Pivot to Cash” to “Pivot to Recovery” in a COVID-19 world?
In this episode of A&M's Global Webcast Series, Managing Directors Markus Lahrkamp of Private Equity Performance Improvement and Ron Orsini of Corporate Performance Improvement, share their insights on the important action steps PE-backed and public companies should take now to ensure they survive the current lock-down and have a strong return to market once the lock-down is over.
Some key concepts that Markus and Ron address include:
Cash is King
- Prioritize liquidity during every phase of the crisis
- Link 13 week cash flow to Sales & Operations Planning
- Bend the Fixed Cost Curve
“Clean Sheet” Approach
- What are necessary vs. non-essential costs
- What cash levels are needed to run the business
- Many businesses will have to push the “reset” button to survive this crisis and come out ahead
Scenario Planning Is Critical
- Your next move depends on your industry, your geography, your market situation
- View the business through the customers’ eyes
- Prepare for the worst, and adjust if it gets better
Contact Markus or Ron if you have any questions or would like to discuss these insights further.
Markus Lahrkamp
Managing Director, Private Equity Performance Improvement
mlahrkamp@alvarezandmarsal.com
917.209.9956
Ron Orsini
Managing Director, Corporate Performance Improvement
rorsini@alvarezandmarsal.com
832.768.4317
Financing Saudi Arabia’s Data Center Build-Out
August 6, 2026
Discover financing strategies for Saudi Arabia's data center build-out, from bankability and project finance to capital structuring and debt advisory.
Section 232 Pharmaceutical Duties: UK Rate Cut to Zero, and the Origin and Section 301 Questions That Follow
August 5, 2026
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.
Enterprise Management Incentive Plans - Recent Changes and Common Pitfalls
August 5, 2026
Enterprise Management Incentive (EMI) option plans have been at the centre of UK employee incentivisation for many years and remain popular with privately owned, fast-growing companies.
Better Data, Better Exits: The New Playbook for Wealth and Insurance Platform Roll-Ups
August 5, 2026
There’s a new value creation imperative for private equity (PE) firms and corporates seeking to roll up financial technology (FinTech) and data platform acquisitions, especially in the extended higher interest rate environment. Many of the traditional value enhancement strategies still matter, but operational platforming—integrating tech, data, and systems—can be a defining competitive advantage in roll-ups.
